- Home
- JFU vs MTVA Comparison
JFU vs MTVA Comparison
Compare JFU & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- MTVA
- Stock Information
- Founded
- JFU 2006
- MTVA 2014
- Country
- JFU China
- MTVA United States
- Employees
- JFU N/A
- MTVA N/A
- Industry
- JFU Finance: Consumer Services
- MTVA
- Sector
- JFU Finance
- MTVA
- Exchange
- JFU Nasdaq
- MTVA NYSE
- Market Cap
- JFU 17.1M
- MTVA 14.3M
- IPO Year
- JFU 2019
- MTVA N/A
- Fundamental
- Price
- JFU $1.40
- MTVA $0.66
- Analyst Decision
- JFU
- MTVA Strong Buy
- Analyst Count
- JFU 0
- MTVA 2
- Target Price
- JFU N/A
- MTVA $7.50
- AVG Volume (30 Days)
- JFU 2.9K
- MTVA 133.9K
- Earning Date
- JFU 01-01-0001
- MTVA 08-13-2025
- Dividend Yield
- JFU N/A
- MTVA N/A
- EPS Growth
- JFU N/A
- MTVA N/A
- EPS
- JFU 0.09
- MTVA N/A
- Revenue
- JFU $40,614,155.00
- MTVA N/A
- Revenue This Year
- JFU N/A
- MTVA N/A
- Revenue Next Year
- JFU N/A
- MTVA N/A
- P/E Ratio
- JFU $15.08
- MTVA N/A
- Revenue Growth
- JFU N/A
- MTVA N/A
- 52 Week Low
- JFU $1.01
- MTVA $0.63
- 52 Week High
- JFU $3.60
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- JFU 50.23
- MTVA N/A
- Support Level
- JFU $1.36
- MTVA N/A
- Resistance Level
- JFU $1.48
- MTVA N/A
- Average True Range (ATR)
- JFU 0.07
- MTVA 0.00
- MACD
- JFU -0.01
- MTVA 0.00
- Stochastic Oscillator
- JFU 21.13
- MTVA 0.00
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.